Takeda Pharmaceutical Co. (NYSE:TAK – Get Free Report) insider Gabriele Ricci sold 25,088 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $429,004.80. Following the completion of the transaction, the insider owned 171,654 shares of the company’s stock, valued at approximately $2,935,283.40. This represents a 12.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Takeda Pharmaceutical Stock Down 0.3%
Takeda Pharmaceutical stock traded down $0.06 during midday trading on Wednesday, hitting $17.42. 2,004,364 shares of the stock were exchanged, compared to its average volume of 4,402,927. Takeda Pharmaceutical Co. has a 1 year low of $12.99 and a 1 year high of $18.90. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.14 and a quick ratio of 0.62. The firm has a market cap of $55.82 billion, a P/E ratio of 51.24 and a beta of -0.08. The company has a 50 day moving average price of $16.49 and a two-hundred day moving average price of $17.13.
Takeda Pharmaceutical (NYSE:TAK – Get Free Report) last announced its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.The company had revenue of $6.90 billion during the quarter. On average, sell-side analysts predict that Takeda Pharmaceutical Co. will post 3.01 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Takeda Pharmaceutical
Analyst Ratings Changes
Several research firms have issued reports on TAK. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Finally, Weiss Ratings lowered shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, July 30th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold”.
Check Out Our Latest Stock Analysis on Takeda Pharmaceutical
About Takeda Pharmaceutical
Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.
Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.
Featured Stories
- Five stocks we like better than Takeda Pharmaceutical
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
